Released Oct 14, 2026, before the open
10-Q filed Nov 5, 2026, 36 days after period end · 0001104659-26-123305
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $24.01M | $11.24M | — | $2.00K |
| Net Income | -$74.72M | -$98.52M | -$23.97M | -$22.79M |
| EPS Diluted |
Verastem, Inc. · CIK 1526119 · Engraved from SEC EDGAR
| -$0.74 |
| -$1.35 |
| -$0.60 |
| -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Verastem estimates net product revenue for the three months ended September 30, 2026 at $23.9 million to $24.1 million, compared to $11.2 million a year earlier, with unaudited preliminary results not reviewed by auditors.¶1¶2¶3
Daniel W. Paterson will retire as President and Chief Executive Officer effective January 1, 2027, and Michael Bailey, 61, will be appointed to the role, with Mr. Paterson expected to serve as a consultant.¶4¶5
As of an October 7, 2026 data cutoff, VS-7375 at 900 mg showed a 50% (4/8) confirmed ORR in 2L PDAC and 41% (9/22) in 2L+, and FDA alignment was reached on a Phase 3 first-line mPDAC design.¶6¶7
Effective October 14, 2026, the Company suspended and terminated the prospectus for its at-the-market common stock offering with Cantor Fitzgerald, and no shares have been sold under it.¶8¶9
On October 7, 2026, the FDA accepted for review the Company's Blister Pack New Drug Application and granted it priority review.¶10